Background: Persistent low-grade immune-inflammatory processes, oxidative and nitrosative stress (O&NS), and hypothalamic-pituitary-adrenal axis activation are integral to the pathophysiology of major depressive disorder (MDD). The microbiome, intestinal compositional changes, and resultant bacterial translocation add a new element to the bidirectional interactions of the gut-brain axis; new evidence implicates these pathways in the patho-aetiology of MDD. In addition, abnormalities in the gut-brain axis are associated with several chronic non-communicable disorders, which frequently co-occur in individuals with MDD, including but not limited to irritable bowel syndrome (IBS), chronic fatigue syndrome (CFS), obesity, and type 2 diabetes mellitus (T2DM). Methods: We searched the PubMed/MEDLINE database up until May 1, 2016 for studies which investigated intestinal dysbiosis and bacterial translocation (the ‘leaky gut') in the pathophysiology of MDD and co-occurring somatic comorbidities with an emphasis on IBS, CFS, obesity, and T2DM. Results: The composition of the gut microbiota is influenced by several genetic and environmental factors (e.g. diet). Several lines of evidence indicate that gut-microbiota-diet interactions play a significant pathophysiological role in MDD and related medical comorbidities. Gut dysbiosis and the leaky gut may influence several pathways implicated in the biology of MDD, including but not limited to immune activation, O&NS, and neuroplasticity cascades. However, methodological inconsistencies and limitations limit comparisons across studies. Conclusions: Intestinal dysbiosis and the leaky gut may constitute a key pathophysiological link between MDD and its medical comorbidities. This emerging literature opens relevant preventative and therapeutic perspectives.

Keywords:
Mood disorders, Obesity, Depression, Diabetes, Microbiota, Chronic fatigue syndrome, Inflammation, Psychiatry, Irritable bowel syndrome, Oxidative stress
1.
Kiecolt-Glaser JK, Derry HM, Fagundes CP: Inflammation: depression fans the flames and feasts on the heat. Am J Psychiatry 2015;172:1075-1091.
2.
Lotrich FE: Inflammatory cytokine-associated depression. Brain Res 2015;1617:113-125.
3.
Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctôt KL: A meta-analysis of cytokines in major depression. Biol Psychiatry 2010;67:446-457.
4.
Liu Y, Ho RC-M, Mak A: Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord 2012;139:230-239.
5.
Moylan S, Berk M, Dean OM, Samuni Y, Williams LJ, O'Neil A, Hayley AC, Pasco JA, Anderson G, Jacka FN: Oxidative and nitrosative stress in depression: why so much stress? Neurosci Biobehav Rev 2014;45:46-62.
6.
Moylan S, Maes M, Wray NR, Berk M: The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry 2013;18:595-606.
7.
Berk M, Williams LJ, Jacka FN, O'Neil A, Pasco JA, Moylan S, Allen NB, Stuart AL, Hayley AC, Byrne ML, Maes M: So depression is an inflammatory disease, but where does the inflammation come from? BMC Med 2013;11:200.
8.
Benros ME, Waltoft BL, Nordentoft M, Ostergaard SD, Eaton WW, Krogh J, Mortensen PB: Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study. JAMA Psychiatry 2013;70:812-820.
9.
Leonard B, Maes M: Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012;36:764-785.
10.
Zheng P, Zeng B, Zhou C, Liu M, Fang Z, Xu X, Zeng L, Chen J, Fan S, Du X, Zhang X, Yang D, Yang Y, Meng H, Li W, Melgiri ND, Licinio J, Wei H, Xie P: Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host's metabolism. Mol Psychiatry 2016;21:786-796.
11.
Jiang H, Ling Z, Zhang Y, Mao H, Ma Z, Yin Y, Wang W, Tang W, Tan Z, Shi J, Li L, Ruan B: Altered fecal microbiota composition in patients with major depressive disorder. Brain Behav Immun 2015;48:186-194.
12.
Ogbonnaya ES, Clarke G, Shanahan F, Dinan TG, Cryan JF, O'Leary OF: Adult hippocampal neurogenesis is regulated by the microbiome. Biol Psychiatry 2015;78:e7-e9.
13.
Foster JA, Neufeld K-AM: Gut-brain axis: how the microbiome influences anxiety and depression. Trends Neurosci 2013;36:305-312.
14.
Maes M, Kubera M, Leunis J-C: The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from Gram-negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro Endocrinol Lett 2008;29:117-124.
15.
Braniste V, Al-Asmakh M, Kowal C, Anuar F, Abbaspour A, Toth M, Korecka A, Bakocevic N, Ng LG, Kundu P, Gulyas B, Halldin C, Hultenby K, Nilsson H, Hebert H, Volpe BT, Diamond B, Pettersson S: The gut microbiota influences blood-brain barrier permeability in mice. Sci Transl Med 2014;6:263ra158.
16.
Diehl GE, Longman RS, Zhang JX, Breart B, Galan C, Cuesta A, Schwab SR, Littman DR: Microbiota restricts trafficking of bacteria to mesenteric lymph nodes by CX3CR1hi cells. Nature 2013;494:116-120.
17.
Whitehead WE, Palsson O, Jones KR: Systematic review of the comorbidity of irritable bowel syndrome with other disorders: What are the causes and implications? Gastroenterology 2002;122:1140-1156.
18.
Nakao M, Nomura S, Yamanaka G, Kumano H, Kuboki T: Assessment of patients by DSM-III-R and DSM-IV in a Japanese psychosomatic clinic. Psychother Psychosom 1998;67:43-49.
19.
Lane TJ, Manu P, Matthews DA: Depression and somatization in the chronic fatigue syndrome. Am J Med 1991;91:335-344.
20.
Maes M, Twisk FN, Ringel K: Inflammatory and cell-mediated immune biomarkers in myalgic encephalomyelitis/chronic fatigue syndrome and depression: inflammatory markers are higher in myalgic encephalomyelitis/chronic fatigue syndrome than in depression. Psychother Psychosom 2012;81:286-295.
21.
Ali S, Stone M, Peters J, Davies M, Khunti K: The prevalence of co-morbid depression in adults with type 2 diabetes: a systematic review and meta-analysis. Diabet Med 2006;23:1165-1173.
22.
Lasserre AM, Glaus J, Vandeleur CL, Marques-Vidal P, Vaucher J, Bastardot F, Waeber G, Vollenweider P, Preisig M: Depression with atypical features and increase in obesity, body mass index, waist circumference, and fat mass: a prospective, population-based study. JAMA Psychiatry 2014;71:880-888.
23.
Dirmaier J, Watzke B, Koch U, Schulz H, Lehnert H, Pieper L, Wittchen HU: Diabetes in primary care: Prospective associations between depression, nonadherence and glycemic control. Psychother Psychosom 2010;79:172-178.
24.
Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T: A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010;464:59-65.
25.
Biasucci G, Rubini M, Riboni S, Morelli L, Bessi E, Retetangos C: Mode of delivery affects the bacterial community in the newborn gut. Early Hum Dev 2010;86(suppl 1):13-15.
26.
Jakobsson HE, Abrahamsson TR, Jenmalm MC, Harris K, Quince C, Jernberg C, Bjorksten B, Engstrand L, Andersson AF: Decreased gut microbiota diversity, delayed Bacteroidetes colonisation and reduced Th1 responses in infants delivered by Caesarean section. Gut 2014;63:559-566.
27.
Roger LC, Costabile A, Holland DT, Hoyles L, McCartney AL: Examination of faecal Bifidobacterium populations in breast- and formula-fed infants during the first 18 months of life. Microbiology 2010;156:3329-3341.
28.
Palmer C, Bik EM, DiGiulio DB, Relman DA, Brown PO: Development of the human infant intestinal microbiota. PLoS Biol 2007;5:e177.
29.
Kashtanova DA, Popenko AS, Tkacheva ON, Tyakht AB, Alexeev DG, Boytsov SA: Association between the gut microbiota and diet: fetal life, early childhood, and further life. Nutrition 2016;32:620-627.
30.
Hildebrandt MA, Hoffmann C, Sherrill-Mix SA, Keilbaugh SA, Hamady M, Chen YY, Knight R, Ahima RS, Bushman F, Wu GD: High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 2009;137:1716-1724.e1711-e1712.
31.
Zhang C, Zhang M, Pang X, Zhao Y, Wang L, Zhao L: Structural resilience of the gut microbiota in adult mice under high-fat dietary perturbations. ISME J 2012;6:1848-1857.
32.
Patterson E, Ryan PM, Cryan JF, Dinan TG, Ross RP, Fitzgerald GF, Stanton C: Gut microbiota, obesity and diabetes. Postgrad Med J 2016;92:286-300.
33.
Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG, Delzenne NM, de Vos WM, Cani PD: Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA 2013;110:9066-9071.
34.
Karlsson CL, Onnerfalt J, Xu J, Molin G, Ahrne S, Thorngren-Jerneck K: The microbiota of the gut in preschool children with normal and excessive body weight. Obesity (Silver Spring) 2012;20:2257-2261.
35.
Wu M, McNulty NP, Rodionov DA, Khoroshkin MS, Griffin NW, Cheng J, Latreille P, Kerstetter RA, Terrapon N, Henrissat B, Osterman AL, Gordon JI: Genetic determinants of in vivo fitness and diet responsiveness in multiple human gut Bacteroides. Science 2015;350:aac5992.
36.
Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R: Recognition of commensal microflora by Toll-like receptors is required for intestinal homeostasis. Cell 2004;118:229-241.
37.
Boren J, Lee WN, Bassilian S, Centelles JJ, Lim S, Ahmed S, Boros LG, Cascante M: The stable isotope-based dynamic metabolic profile of butyrate-induced HT29 cell differentiation. J Biol Chem 2003;278:28395-28402.
38.
Ogawa H, Rafiee P, Fisher PJ, Johnson NA, Otterson MF, Binion DG: Butyrate modulates gene and protein expression in human intestinal endothelial cells. Biochem Biophys Res Commun 2003;309:512-519.
39.
Cryan JF, Dinan TG: Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 2012;13:701-712.
40.
Dhiman RK: Gut microbiota and hepatic encephalopathy. Metab Brain Dis 2013;28:321-326.
41.
Ghanizadeh A, Berk M: Molecular hydrogen: an overview of its neurobiological effects and therapeutic potential for bipolar disorder and schizophrenia. Med Gas Res 2013;3:11.
42.
Nemeroff CB, Vale WW: The neurobiology of depression: inroads to treatment and new drug discovery. J Clin Psychiatry 2005;66:5.
43.
Pariante CM: The glucocorticoid receptor: part of the solution or part of the problem? J Psychopharmacol 2006;20:79-84.
44.
Morris G, Berk M: The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders. BMC Med 2015;13:68.
45.
Naseribafrouei A, Hestad K, Avershina E, Sekelja M, Linlokken A, Wilson R, Rudi K: Correlation between the human fecal microbiota and depression. Neurogastroenterol Motil 2014;26:1155-1162.
46.
Berg RD, Garlington AW: Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model. Infection and Immunity 1979;23:403-411.
47.
Wiest R, Garcia-Tsao G: Bacterial translocation (BT) in cirrhosis. Hepatology 2005;41:422-433.
48.
Maes M: The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro Endocrinol Lett 2008;29:287-291.
49.
Grigoleit JS, Kullmann JS, Wolf OT, Hammes F, Wegner A, Jablonowski S, Engler H, Gizewski E, Oberbeck R, Schedlowski M: Dose-dependent effects of endotoxin on neurobehavioral functions in humans. PLoS One 2011;6:e28330.
50.
Baranyi A, Meinitzer A, Stepan A, Putz-Bankuti C, Breitenecker RJ, Stauber R, Kapfhammer HP, Rothenhausler HB: A biopsychosocial model of interferon-α-induced depression in patients with chronic hepatitis c infection. Psychother Psychosom 2013;82:332-340.
51.
Mahajan S, Avasthi A, Grover S, Chawla YK: Incidence of depression in patients with chronic hepatitis C receiving combination therapy of pegylated interferon-α and ribavirin. Psychother Psychosom 2014;83:308-309.
52.
Lucas K, Maes M: Role of the Toll-like receptor (TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 pathway. Mol Neurobiol 2013;48:190-204.
53.
Chan ED, Riches DW: IFN-γ+ LPS induction of iNOS is modulated by ERK, JNK/SAPK, and p38 MAPK in a mouse macrophage cell line. Am J Physiol Cell Physiol 2001;280:C441-C450.
54.
Wischmeyer PE: Glutamine: role in gut protection in critical illness. Curr Opin Clin Nutr Metab Care 2006;9:607-612.
55.
Pai K, Sodhi A: Effect of cisplatin, rIFN-Y, LPS and MDP on release of H2O2, O2-and lysozyme from human monocytes in vitro. Indian J Exp Biol 1991;29:910-915.
56.
Lewis C, McCarthy S, Lorenzen J, McGee J: Differential effects of LPS, IFN-γ and TNF-α- on the secretion of lysozyme by individual human mononuclear phagocytes: relationship to cell maturity. Immunology 1990;69:402.
57.
Maes M, Kubera M, Leunis JC, Berk M, Geffard M, Bosmans E: In depression, bacterial translocation may drive inflammatory responses, oxidative and nitrosative stress (O&NS), and autoimmune responses directed against O&NS-damaged neoepitopes. Acta Psychiatr Scand 2013;127:344-354.
58.
Clark JM, Diehl AM: Hepatic steatosis and type 2 diabetes mellitus. Curr Diab Rep 2002;2:210-215.
59.
Iovine NM, Pursnani S, Voldman A, Wasserman G, Blaser MJ, Weinrauch Y: Reactive nitrogen species contribute to innate host defense against Campylobacter jejuni. Infect Immun 2008;76:986-993.
60.
Lin WN, Lin CC, Cheng HY, Yang CM: Regulation of cyclooxygenase-2 and cytosolic phospholipase A2 gene expression by lipopolysaccharide through the RNA-binding protein HUR: involvement of NADPH oxidase, reactive oxygen species and mitogen-activated protein kinases. Br J Pharmacol 2011;163:1691-1706.
61.
Check J, Byrd CL, Menio J, Rippe RA, Hines IN, Wheeler MD: Src kinase participates in LPS-induced activation of NADPH oxidase. Mol Immunol 2010;47:756-762.
62.
Peng T, Lu X, Feng Q: NADH oxidase signaling induces cyclooxygenase-2 expression during lipopolysaccharide stimulation in cardiomyocytes. FASEB J 2005;19:293-295.
63.
Mehlhase J, Gieche J, Ullrich O, Sitte N, Grune T: LPS-induced protein oxidation and proteolysis in BV-2 microglial cells. IUBMB Life 2000;50:331-335.
64.
Tyagi E, Agrawal R, Nath C, Shukla R: Effect of melatonin on neuroinflammation and acetylcholinesterase activity induced by LPS in rat brain. Eur J Pharmacol 2010;640:206-210.
65.
Gawryluk JW, Wang JF, Andreazza AC, Shao L, Young LT: Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol 2011;14:123-130.
66.
Sah SP, Tirkey N, Kuhad A, Chopra K: Effect of quercetin on lipopolysaccharide induced-sickness behavior and oxidative stress in rats. Indian J Pharmacol 2011;43:192.
67.
Hall DM, Buettner GR, Oberley LW, Xu L, Matthes RD, Gisolfi CV: Mechanisms of circulatory and intestinal barrier dysfunction during whole body hyperthermia. Am J Physiol Heart Circ Physiol 2001;280:H509-H521.
68.
Iseme RA, McEvoy M, Kelly B, Agnew L, Attia J, Walker FR: Autoantibodies and depression: evidence for a causal link? Neurosci Biobehav Rev 2014;40:62-79.
69.
Brandt LJ, Locke GR, Olden K, Quigley EM, Schoenfeld P, Schuster M, Talley N: An evidence-based approach to the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002;97(suppl):S7-S26.
70.
Drossman DA, Camilleri M, Mayer EA, Whitehead WE: AGA technical review on irritable bowel syndrome. Gastroenterology 2002;123:2108-2131.
71.
Thompson W, Heaton K, Smyth G, Smyth C: Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. Gut 2000;46:78-82.
72.
Quigley E: Current concepts of the irritable bowel syndrome. Scand J Gastroenterol Suppl 2003;38:1-8.
73.
Palsson OS, Drossman DA: Psychiatric and psychological dysfunction in irritable bowel syndrome and the role of psychological treatments. Gastroenterol Clin North Am 2005;34:281-303.
74.
Whorwell P, Prior A, Colgan S: Hypnotherapy in severe irritable bowel syndrome: Further experience. Gut 1987;28:423-425.
75.
Drossman DA, Whitehead WE, Toner BB, Diamant N, Hu YJ, Bangdiwala SI, Jia H: What determines severity among patients with painful functional bowel disorders? Am J Gastroenterol 2000;95:974-980.
76.
Zhou Q, Zhang B, Verne GN: Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain 2009;146:41-46.
77.
Gecse K, Róka R, Séra T, Rosztóczy A, Annaházi A, Izbéki F, Nagy F, Molnár T, Szepes Z, Pávics L: Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis. Digestion 2011;85:40-46.
78.
Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, Wilson I: Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002;122:1778-1783.
79.
Collins S, Denou E, Verdu E, Bercik P: The putative role of the intestinal microbiota in the irritable bowel syndrome. Dig Liver Dis 2009;41:850-853.
80.
Rajilić-Stojanović M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, de Vos WM: Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011;141:1792-1801.
81.
An S, Zong G, Wang Z, Shi J, Du H, Hu J: Expression of inducible nitric oxide synthase in mast cells contributes to the regulation of inflammatory cytokines in irritable bowel syndrome with diarrhea. Neurogastroenterol Motil 2016;28:1083-1093.
82.
Liebregts T, Adam B, Bredack C, Röth A, Heinzel S, Lester S, Downie-Doyle S, Smith E, Drew P, Talley NJ: Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007;132:913-920.
83.
Dinan TG, Quigley EM, Ahmed SM, Scully P, O'Brien S, O'Mahony L, O'Mahony S, Shanahan F, Keeling PN: Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 2006;130:304-311.
84.
Reus V, Joseph M, Dallman M: ACTH levels after the dexamethasone suppression test in depression. N Engl J Med 1982;306:238.
85.
Stokes PE: The potential role of excessive cortisol induced by HPA hyperfunction in the pathogenesis of depression. Eur Neuropsychopharmacol 1995;5:77-82.
86.
Dlugosz A, Nowak P, D'Amato M, Mohammadian Kermani G, Nyström J, Abdurahman S, Lindberg G: Increased serum levels of lipopolysaccharide and antiflagellin antibodies in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 2015;27:1747-1754.
87.
Öhman L, Isaksson S, Lindmark A-C, Posserud I, Stotzer P-O, Strid H, Sjövall H, Simrén M: T-cell activation in patients with irritable bowel syndrome. Am J Gastroenterol 2009;104:1205-1212.
88.
Lindmark A, Isaksson S, Posserud I, Strid H, Sjövall H, Simrén M: B-cell activation in patients with irritable bowel syndrome (IBS). Neurogastroenterol Motil 2009;21:644-e627.
89.
O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O'Sullivan GC, Kiely B, Collins JK, Shanahan F: Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541-551.
90.
Prakash S, Rodes L, Coussa-Charley M, Tomaro-Duchesneau C: Gut microbiota: next frontier in understanding human health and development of biotherapeutics. Biologics 2011;5:71-86.
91.
O'Mahony C, Scully P, O'Mahony D, Murphy S, O'Brien F, Lyons A, Sherlock G, MacSharry J, Kiely B, Shanahan F: Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NF-κB activation. PLoS Pathog 2008;4:e1000112.
92.
Distrutti E, Monaldi L, Ricci P, Fiorucci S: Gut microbiota role in irritable bowel syndrome: new therapeutic strategies. World J Gastroenterol 2016;22:2219-2241.
93.
Griffith JP, Zarrouf FA: A systematic review of chronic fatigue syndrome: don't assume it's depression. Prim Care Companion J Clin Psychiatry 2008;10:120.
94.
Moylan S, Eyre HA, Berk M: Chronic fatigue syndrome: what is it and how to treat? Lancet Psychiatry 2015;2:1044-1045.
95.
Janssens KA, Zijlema WL, Joustra ML, Rosmalen JG: Mood and anxiety disorders in chronic fatigue syndrome, fibromyalgia, and irritable bowel syndrome: results from the lifelines cohort study. Psychosom Med 2015;77:449-457.
96.
Fletcher MA, Zeng XR, Barnes Z, Levis S, Klimas NG: Plasma cytokines in women with chronic fatigue syndrome. J Transl Med 2009;7:96.
97.
Lorusso L, Mikhaylova SV, Capelli E, Ferrari D, Ngonga GK, Ricevuti G: Immunological aspects of chronic fatigue syndrome. Autoimmun Rev 2009;8:287-291.
98.
Bansal AS, Bradley AS, Bishop KN, Kiani-Alikhan S, Ford B: Chronic fatigue syndrome, the immune system and viral infection. Brain Behav Immun 2012;26:24-31.
99.
Myhill S, Booth NE, McLaren-Howard J: Chronic fatigue syndrome and mitochondrial dysfunction. Int J Clin Exp Med 2009;2:1-16.
100.
Morris G, Maes M: Oxidative and nitrosative stress and immune-inflammatory pathways in patients with myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS). Curr Neuropharmacol 2014;12:168-185.
101.
Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E: Increased 8-hydroxy-deoxyguanosine, a marker of oxidative damage to DNA, in major depression and myalgic encephalomyelitis/chronic fatigue syndrome. Neuro Endocrinol Lett 2009;30:715-722.
102.
Maes M, Mihaylova I, Leunis J-C: Increased serum IgA and IgM against LPS of enterobacteria in chronic fatigue syndrome (CFS): indication for the involvement of Gram-negative enterobacteria in the etiology of CFS and for the presence of an increased gut-intestinal permeability. J Affect Disord 2007;99:237-240.
103.
Maes M, Twisk FN, Kubera M, Ringel K, Leunis J-C, Geffard M: Increased IgA responses to the LPS of commensal bacteria is associated with inflammation and activation of cell-mediated immunity in chronic fatigue syndrome. J Affect Disord 2012;136:909-917.
104.
Logan AC, Rao AV, Irani D: Chronic fatigue syndrome: lactic acid bacteria may be of therapeutic value. Med Hypotheses 2003;60:915-923.
105.
Frémont M, Coomans D, Massart S, De Meirleir K: High-throughput 16S rRNA gene sequencing reveals alterations of intestinal microbiota in myalgic encephalomyelitis/chronic fatigue syndrome patients. Anaerobe 2013;22:50-56.
106.
Lakhan SE, Kirchgessner A: Gut inflammation in chronic fatigue syndrome. Nutr Metab (Lond) 2010;7:79.
107.
Maes M, Ringel K, Kubera M, Anderson G, Morris G, Galecki P, Geffard M: In myalgic encephalomyelitis/chronic fatigue syndrome, increased autoimmune activity against 5-HT is associated with immuno-inflammatory pathways and bacterial translocation. J Affect Disord 2013;150:223-230.
108.
Morris G, Berk M, Galecki P, Maes M: The emerging role of autoimmunity in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Mol Neurobiol 2014;49:741-756.
109.
Maes M, Mihaylova I, Kubera M, Bosmans E: Not in the mind but in the cell: increased production of cyclo-oxygenase-2 and inducible no synthase in chronic fatigue syndrome. Neuro Endocrinol Lett 2007;28:463-469.
110.
Maes M, Mihaylova I, Leunis J-C: Chronic fatigue syndrome is accompanied by an IgM-related immune response directed against neoepitopes formed by oxidative or nitrosative damage to lipids and proteins. Neuro Endocrinol Lett 2006;27:615-622.
111.
Maes M, Mihaylova I, Leunis J-C: Increased serum IgM antibodies directed against phosphatidyl inositol (PI) in chronic fatigue syndrome (CFS) and major depression: evidence that an IgM-mediated immune response against PI is one factor underpinning the comorbidity between both CFS and depression. Neuro Endocrinol Lett 2007;28:861-867.
112.
Gaab J, Rohleder N, Heitz V, Engert V, Schad T, Schürmeyer TH, Ehlert U: Stress-induced changes in LPS-induced pro-inflammatory cytokine production in chronic fatigue syndrome. Psychoneuroendocrinology 2005;30:188-198.
113.
Hiles SA, Revesz D, Lamers F, Giltay E, Penninx BW: Bidirectional prospective associations of metabolic syndrome components with depression, anxiety, and antidepressant use. Depress Anxiety 2016;33:754-764.
114.
Vancampfort D, Mitchell AJ, De Hert M, Sienaert P, Probst M, Buys R, Stubbs B: Type 2 diabetes in patients with major depressive disorder: a meta-analysis of prevalence estimates and predictors. Depress Anxiety 2015;32:763-773.
115.
Jacka FN, Sacks G, Berk M, Allender S: Food policies for physical and mental health. BMC Psychiatry 2014;14:132.
116.
Dipnall JF, Pasco JA, Meyer D, Berk M, Williams LJ, Dodd S, Jacka FN: The association between dietary patterns, diabetes and depression. J Affect Disord 2015;174:215-224.
117.
Liu CS, Carvalho AF, McIntyre RS: Towards a ‘metabolic' subtype of major depressive disorder: shared pathophysiological mechanisms may contribute to cognitive dysfunction. CNS Neurol Disord Drug Targets 2014;13:1693-1707.
118.
Mujica-Parodi L, Renelique R, Taylor M: Higher body fat percentage is associated with increased cortisol reactivity and impaired cognitive resilience in response to acute emotional stress. Int J Obes (Lond) 2009;33:157-165.
119.
Jones A, McMillan MR, Jones RW, Kowalik GT, Steeden JA, Deanfield JE, Pruessner JC, Taylor AM, Muthurangu V: Adiposity is associated with blunted cardiovascular, neuroendocrine and cognitive responses to acute mental stress. PLoS One 2012;7:e39143.
120.
Stetler C, Miller GE: Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. Psychosom Med 2011;73:114-126.
121.
Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N: Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract 2014;105:141-150.
122.
Debnath M, Agrawal S, Agrawal A, Dubey GP: Metaflammatory responses during obesity: pathomechanism and treatment. Obes Res Clin Pract 2016;10:103-113.
123.
Pickup J, Mattock M, Chusney G, Burt D: NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997;40:1286-1292.
124.
Herder C, Illig T, Rathmann W, Martin S, Haastert B, Müller-Scholze S, Holle R, Thorand B, Koenig W, Wichmann H: Inflammation and type 2 diabetes: results from KORA Augsburg. Gesundheitswesen 2005;67:S115-S121.
125.
Choi J, Joseph L, Pilote L: Obesity and C-reactive protein in various populations: a systematic review and meta-analysis. Obes Rev 2013;14:232-244.
126.
Tsigos C, Kyrou I, Chala E, Tsapogas P, Stavridis JC, Raptis SA, Katsilambros N: Circulating tumor necrosis factor alpha concentrations are higher in abdominal versus peripheral obesity. Metabolism 1999;48:1332-1335.
127.
Spranger J, Kroke A, Möhlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF: Inflammatory cytokines and the risk to develop type 2 diabetes results of the prospective population-based European prospective investigation into cancer and nutrition (EPIC)-Potsdam study. Diabetes 2003;52:812-817.
128.
Lee C, Adler A, Sandhu M, Sharp S, Forouhi N, Erqou S, Luben R, Bingham S, Khaw K, Wareham N: Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis. Diabetologia 2009;52:1040-1047.
129.
Monk JM, Hou TY, Turk HF, Weeks B, Wu C, McMurray DN, Chapkin RS: Dietary N-3 polyunsaturated fatty acids (PUFA) decrease obesity-associated Th17 cell-mediated inflammation during colitis. PLoS One 2012;7:e49739.
130.
Slyepchenko A, Maes M, Kohler CA, Anderson G, Quevedo J, Alves GS, Berk M, Fernandes BS, Carvalho AF: T helper 17 cells may drive neuroprogression in major depressive disorder: proposal of an integrative model. Neurosci Biobehav Rev 2016;64:83-100.
131.
Kohlgruber A, Lynch L: Adipose tissue inflammation in the pathogenesis of type 2 diabetes. Curr Diab Rep 2015;15:92.
132.
Grant RW, Dixit VD: Adipose tissue as an immunological organ. Obesity (Silver Spring) 2015;23:512-518.
133.
Nishikawa T, Edelstein D, Du XL, Yamagishi S-i, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes H-P: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000;404:787-790.
134.
Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J: Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007;39:44-84.
135.
Rupérez AI, Gil A, Aguilera CM: Genetics of oxidative stress in obesity. Int J Mol Sci 2014;15:3118-3144.
136.
VanderJagt DJ, Harrison JM, Ratliff DM, Hunsaker LA, Vander Jagt DL: Oxidative stress indices in IDDM subjects with and without long-term diabetic complications. Clin Biochem 2001;34:265-270.
137.
Creely SJ, McTernan PG, Kusminski CM, Da Silva N, Khanolkar M, Evans M, Harte A, Kumar S: Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 2007;292:E740-E747.
138.
Gnauck A, Lentle RG, Kruger MC: The characteristics and function of bacterial lipopolysaccharides and their endotoxic potential in humans. Int Rev Immunol 2015:1-31.
139.
Karlsson FH, Tremaroli V, Nookaew I, Bergstrom G, Behre CJ, Fagerberg B, Nielsen J, Backhed F: Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 2013;498:99-103.
140.
Hersoug LG, Moller P, Loft S: Gut microbiota-derived lipopolysaccharide uptake and trafficking to adipose tissue: implications for inflammation and obesity. Obes Rev 2016;17:297-312.
141.
Harte AL, Varma MC, Tripathi G, McGee KC, Al-Daghri NM, Al-Attas OS, Sabico S, O'Hare JP, Ceriello A, Saravanan P, Kumar S, McTernan PG: High fat intake leads to acute postprandial exposure to circulating endotoxin in type 2 diabetic subjects. Diabetes Care 2012;35:375-382.
142.
Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, Griffin NW, Lombard V, Henrissat B, Bain JR, Muehlbauer MJ, Ilkayeva O, Semenkovich CF, Funai K, Hayashi DK, Lyle BJ, Martini MC, Ursell LK, Clemente JC, Van Treuren W, Walters WA, Knight R, Newgard CB, Heath AC, Gordon JI: Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 2013;341:1241214.
143.
Naseribafrouei A, Hestad K, Avershina E, Sekelja M, Linløkken A, Wilson R, Rudi K: Correlation between the human fecal microbiota and depression. Neurogastroenterol Motil 2014;26:1155-1162.
144.
Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI: Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 2005;102:11070-11075.
145.
Zhang X, Shen D, Fang Z, Jie Z, Qiu X, Zhang C, Chen Y, Ji L: Human gut microbiota changes reveal the progression of glucose intolerance. PLoS One 2013;8:e71108.
146.
Brunoni AR, Lopes M, Fregni F: A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 2008;11:1169-1180.
147.
Yu YB, Zuo XL, Zhao QJ, Chen FX, Yang J, Dong YY, Wang P, Li YQ: Brain-derived neurotrophic factor contributes to abdominal pain in irritable bowel syndrome. Gut 2012;61:685-694.
148.
Chen R, Liang FX, Moriya J, Yamakawa J, Sumino H, Kanda T, Takahashi T: Chronic fatigue syndrome and the central nervous system. J Int Med Res 2008;36:867-874.
149.
Li B, Lang N, Cheng ZF: Serum levels of brain-derived neurotrophic factor are associated with diabetes risk, complications, and obesity: a cohort study from Chinese patients with type 2 diabetes. Mol Neurobiol 2015, Epub ahead of print.
150.
Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux J-J, Blugeon S, Bridonneau C, Furet J-P, Corthier G: Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008;105:16731-16736.
151.
Duncan SH, Hold GL, Harmsen HJ, Stewart CS, Flint HJ: Growth requirements and fermentation products of Fusobacterium prausnitzii, and a proposal to reclassify it as Faecalibacterium prausnitzii gen. nov., comb. nov. Int J Syst Evol Microbiol 2002;52:2141-2146.
152.
Walker AW, Duncan SH, Leitch ECM, Child MW, Flint HJ: pH and peptide supply can radically alter bacterial populations and short-chain fatty acid ratios within microbial communities from the human colon. Appl Environ Microbiol 2005;71:3692-3700.
153.
Macfarlane GT, Gibson GR: Carbohydrate fermentation, energy transduction and gas metabolism in the human large intestine; in Mackie RI, White BA (eds): Gastrointestinal Microbiology. New York, Springer, 1997, pp 269-318.
154.
Lewis K, Lutgendorff F, Phan V, Söderholm JD, Sherman PM, McKay DM: Enhanced translocation of bacteria across metabolically stressed epithelia is reduced by butyrate. Inflamm Bowel Dis 2010;16:1138-1148.
155.
Peng L, Li Z-R, Green RS, Holzman IR, Lin J: Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of amp-activated protein kinase in Caco-2 cell monolayers. J Nutr 2009;139:1619-1625.
156.
Lin HV, Frassetto A, Kowalik EJ Jr, Nawrocki AR, Lu MM, Kosinski JR, Hubert JA, Szeto D, Yao X, Forrest G: Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS One 2012;7:e35240.
157.
Gérard P: Metabolism of cholesterol and bile acids by the gut microbiota. Digestion 2013;3:14-24.
158.
Dvorak K, Payne CM, Chavarria M, Ramsey L, Dvorakova B, Bernstein H, Holubec H, Sampliner RE, Guy N, Condon A: Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage: relevance to the pathogenesis of Barrett's oesophagus. Gut 2007;56:763-771.
159.
Clavel T, Duck W, Charrier C, Wenning M, Elson C, Haller D: Enterorhabdus caecimuris sp. nov., a member of the family Coriobacteriaceae isolated from a mouse model of spontaneous colitis, and emended description of the genus Enterorhabdus Clavel et al. 2009. Int J Syst Evol Microbiol 2010;60:1527-1531.
160.
Turnbaugh PJ: Microbiology: fat, bile and gut microbes. Nature 2012;487:47-48.
161.
Ridlon JM, Kang D-J, Hylemon PB: Bile salt biotransformations by human intestinal bacteria. J Lipid Res 2006;47:241-259.
162.
Song Y, Könönen E, Rautio M, Liu C, Bryk A, Eerola E, Finegold SM: Alistipes onderdonkii sp. nov. and Alistipes shahii sp. nov., of human origin. Int J Syst Evol Microbiol 2006;56:1985-1990.
163.
Saulnier DM, Riehle K, Mistretta TA, Diaz MA, Mandal D, Raza S, Weidler EM, Qin X, Coarfa C, Milosavljevic A: Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology 2011;141:1782-1791.
164.
David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA: Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014;505:559-563.
165.
Elinav E, Strowig T, Kau AL, Henao-Mejia J, Thaiss CA, Booth CJ, Peaper DR, Bertin J, Eisenbarth SC, Gordon JI: NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 2011;145:745-757.
166.
Duck LW, Walter MR, Novak J, Kelly D, Tomasi M, Cong Y, Elson CO: Isolation of flagellated bacteria implicated in Crohn's disease. Inflamm Bowel Dis 2007;13:1191-1201.
167.
Mass M, Kubera M, Leunis J-C: The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from Gram-negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro Endocrinol Lett 2008;29:117-124.
168.
Maes M, Kubera M, Leunis J-C, Berk M: Increased IgA and IgM responses against gut commensals in chronic depression: further evidence for increased bacterial translocation or leaky gut. J Affect Disord 2012;141:55-62.
169.
Fleissner CK, Huebel N, El-Bary MMA, Loh G, Klaus S, Blaut M: Absence of intestinal microbiota does not protect mice from diet-induced obesity. Br J Nutr 2010;104:919-929.
170.
Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, Calder PC, Sanders ME: Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014;11:506-514.
171.
Phillips JGP: The treatment of melancholia by the lactic acid bacillus. Br J Psychiatry 1910;56:422-NP.
172.
Slyepchenko A, Carvalho AF, Cha DS, Kasper S, McIntyre RS: Gut emotions - mechanisms of action of probiotics as novel therapeutic targets for depression and anxiety disorders. CNS Neurol Disord Drug Targets 2014;13:1770-1786.
173.
Benton D, Williams C, Brown A: Impact of consuming a milk drink containing a probiotic on mood and cognition. Eur J Clin Nutr 2007;61:355-361.
174.
Steenbergen L, Sellaro R, van Hemert S, Bosch JA, Colzato LS: A randomized controlled trial to test the effect of multispecies probiotics on cognitive reactivity to sad mood. Brain Behav Immun 2015;48:258-264.
175.
Didari T, Mozaffari S, Nikfar S, Abdollahi M: Effectiveness of probiotics in irritable bowel syndrome: updated systematic review with meta-analysis. World J Gastroenterol 2015;21:3072-3084.
176.
Rao AV, Bested AC, Beaulne TM, Katzman MA, Iorio C, Berardi JM, Logan AC: A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathog 2009;1:6.
177.
Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM, Muccioli GG, Delzenne NM: Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009;58:1091-1103.
178.
Kobyliak N, Conte C, Cammarota G, Haley AP, Styriak I, Gaspar L, Fusek J, Rodrigo L, Kruzliak P: Probiotics in prevention and treatment of obesity: a critical view. Nutr Metab (Lond) 2016;13:14.
179.
Sun J, Buys N: Effects of probiotics consumption on lowering lipids and CVD risk factors: a systematic review and meta-analysis of randomized controlled trials. Ann Med 2015;47:430-440.
180.
Tazoe H, Otomo Y, Kaji I, Tanaka R, Karaki SI, Kuwahara A: Roles of short-chain fatty acids receptors, GPR41 and GPR43 on colonic functions. J Physiol Pharmacol 2008;59(suppl 2):251-262.
181.
Kimura I, Ozawa K, Inoue D, Imamura T, Kimura K, Maeda T, Terasawa K, Kashihara D, Hirano K, Tani T, Takahashi T, Miyauchi S, Shioi G, Inoue H, Tsujimoto G: The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun 2013;4:1829.
182.
Lorenzi M, Ploug UJ, Vega G, Jansen JP: Liraglutide vs other daily GLP-1 analogues in people with type 2 diabetes: a network meta-analysis. Value Health 2015;18:A598-A599.
183.
McIntyre RS, Powell AM, Kaidanovich-Beilin O, Soczynska JK, Alsuwaidan M, Woldeyohannes HO, Kim AS, Gallaugher LA: The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individuals with mood disorders. Behav Brain Res 2013;237:164-171.
184.
Pineiro M, Asp NG, Reid G, Macfarlane S, Morelli L, Brunser O, Tuohy K: FAO technical meeting on prebiotics. J Clin Gastroenterol 2008;42(suppl 3, pt 2):S156-S159.
185.
Roberfroid M: Functional food concept and its application to prebiotics. Dig Liver Dis 2002;34(suppl 2):S105-S110.
186.
Fond G, Boukouaci W, Chevalier G, Regnault A, Eberl G, Hamdani N, Dickerson F, Macgregor A, Boyer L, Dargel A, Oliveira J, Tamouza R, Leboyer M: The ‘psychomicrobiotic': targeting microbiota in major psychiatric disorders: a systematic review. Pathol Biol (Paris) 2015;63:35-42.
187.
Yoo JY, Kim SS: Probiotics and prebiotics: Present status and future perspectives on metabolic disorders. Nutrients 2016;8:173.
188.
Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, Bewtra M, Knights D, Walters WA, Knight R, Sinha R, Gilroy E, Gupta K, Baldassano R, Nessel L, Li H, Bushman FD, Lewis JD: Linking long-term dietary patterns with gut microbial enterotypes. Science 2011;334:105-108.
189.
O'Keefe SJ, Li JV, Lahti L: Fat, fibre and cancer risk in African Americans and rural Africans. Nat Commun 2015;6:6342.
190.
Murphy EA, Velazquez KT, Herbert KM: Influence of high-fat diet on gut microbiota: a driving force for chronic disease risk. Curr Opin Clin Nutr Metab Care 2015;18:515-520.
191.
Shen W, Wolf PG, Carbonero F, Zhong W, Reid T, Gaskins HR, McIntosh MK: Intestinal and systemic inflammatory responses are positively associated with sulfidogenic bacteria abundance in high-fat-fed male C57BL/6J mice. J Nutr 2014;144:1181-1187.
192.
Sarris J, Logan AC, Akbaraly TN, Amminger GP, Balanza-Martinez V, Freeman MP, Hibbeln J, Matsuoka Y, Mischoulon D, Mizoue T, Nanri A, Nishi D, Ramsey D, Rucklidge JJ, Sanchez-Villegas A, Scholey A, Su KP, Jacka FN: Nutritional medicine as mainstream in psychiatry. Lancet Psychiatry 2015;2:271-274.
193.
Lai JS, Hiles S, Bisquera A, Hure AJ, McEvoy M, Attia J: A systematic review and meta-analysis of dietary patterns and depression in community-dwelling adults. Am J Clin Nutr 2014;99:181-197.
194.
Sanchez-Villegas A, Martinez-Gonzalez MA, Estruch R, Salas-Salvado J, Corella D, Covas MI, Aros F, Romaguera D, Gomez-Gracia E, Lapetra J, Pinto X, Martinez JA, Lamuela-Raventos RM, Ros E, Gea A, Warnberg J, Serra-Majem L: Mediterranean dietary pattern and depression: the PREDIMED randomized trial. BMC Med 2013;11:208.
195.
Opie RS, O'Neil A, Itsiopoulos C, Jacka FN: The impact of whole-of-diet interventions on depression and anxiety: a systematic review of randomised controlled trials. Public Health Nutr 2015;18:2074-2093.
196.
Jacka FN, Pasco JA, Williams LJ, Mann N, Hodge A, Brazionis L, Berk M: Red meat consumption and mood and anxiety disorders. Psychother Psychosom 2012;81:196-198.
197.
Pasco JA, Williams LJ, Brennan-Olsen SL, Berk M, Jacka FN: Milk consumption and the risk for incident major depressive disorder. Psychother Psychosom 2015;84:384-386.
198.
Dash S, Clarke G, Berk M, Jacka FN: The gut microbiome and diet in psychiatry: focus on depression. Curr Opin Psychiatry 2015;28:1-6.
199.
Opie RS, Itsiopoulos C, Parletta N, Sanchez-Villegas A, Akbaraly TN, Ruusunen A, Jacka FN: Dietary recommendations for the prevention of depression. Nutr Neurosci 2015, Epub ahead of print.
200.
O'Neil A, Berk M, Itsiopoulos C, Castle D, Opie R, Pizzinga J, Brazionis L, Hodge A, Mihalopoulos C, Chatterton ML, Dean OM, Jacka FN: A randomised, controlled trial of a dietary intervention for adults with major depression (the ‘SMILES' trial): study protocol. BMC Psychiatry 2013;13:114.
201.
Moayyedi P, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Ford AC: The effect of dietary intervention on irritable bowel syndrome: a systematic review. Clin Transl Gastroenterol 2015;6:e107.
202.
Johnston BC, Kanters S, Bandayrel K, Wu P, Naji F, Siemieniuk RA, Ball GD, Busse JW, Thorlund K, Guyatt G, Jansen JP, Mills EJ: Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis. JAMA 2014;312:923-933.
203.
Huang XL, Pan JH, Chen D, Chen J, Chen F, Hu TT: Efficacy of lifestyle interventions in patients with type 2 diabetes: a systematic review and meta-analysis. Eur J Intern Med 2016;27:37-47.
204.
Kassinen A, Krogius-Kurikka L, Mäkivuokko H, Rinttilä T, Paulin L, Corander J, Malinen E, Apajalahti J, Palva A: The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007;133:24-33.
205.
Isabel M-I, Lidia S-A, Pablo P-M, Cristina A-L, Fernando C, Francisco T, Isabel Q-OM: Red wine polyphenols modulate fecal microbiota and reduce markers of the metabolic syndrome in obese patients. Food Funct 2016;7:1775-1787.
206.
Haro C, Montes-Borrego M, Rangel-Zúñiga OA, Alcalá-Díaz JF, Gómez-Delgado F, Pérez-Martínez P, Delgado-Lista J, Quintana-Navarro GM, Tinahones FJ, Landa BB: Two healthy diets modulate gut microbial community improving insulin sensitivity in a human obese population. J Clin Endocrinol Metab 2015;101:233-242.
207.
Fava GA, Guidi J, Grandi S, Hasler G: The missing link between clinical states and biomarkers in mental disorders. Psychother Psychosom 2014;83:136-141.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.